Analysts’ Viewpoint
Ceftriaxone is the most common antibiotic used in the treatment of urinary tract infections, intra-abdominal infections, endocarditis, and other bacterial infections. Availability of generic and branded versions of ceftriaxone in parenteral formulations (Rocephin) is driving the global ceftriaxone market. Most ceftriaxone products are used off-label for several indications. Generic versions of ceftriaxone offer cost-effective treatments. This is likely to present significant opportunities for market progress in the next few years, especially in developing countries.
Demand for ceftriaxone injection is rising in countries in Asia, such as China and India, due to high incidence rate of chronic diseases and growth in need for effective treatment options. Manufacturers are striving to come up with generic versions of ceftriaxone to meet the rising demand across the globe.
Ceftriaxone is a cephalosporin beta-lactam antibiotic that is used to treat bacterial infections caused by gram-positive, typically susceptible organisms. In vitro testing has shown that ceftriaxone is active against gram-positive, gram-negative, and anaerobic bacteria. Ceftriaxone's bactericidal effect is caused by its inhibition of cell wall production, which is mediated by its binding to penicillin-binding proteins (PBPs).
Ceftriaxone is administered intravenously or intramuscularly through injection. If taken orally, ceftriaxone has a bioavailability of less than 1%. It is most commonly used for urinary tract infections, intra-abdominal infections, endocarditis, acute bacterial otitis media, meningitis, and pneumonia. Ceftriaxone is also utilized as the first-line treatment for neurosyphilis in patients allergic to penicillin. Ceftriaxone injection is also given before certain types of surgery to prevent infections that could develop after an operation. Side effects of ceftriaxone include pain, tenderness, hardness, pale skin, diarrhea, weakness, and shortness of breath when exercising. However, ceftriaxone medicine is ineffective against cold, flu, or other viral infections. The medicine is available with a doctor’s prescription.
Increase in incidence of urinary tract infections, rise in awareness among people, and surge in geriatric population prone to bacterial diseases are likely to augment global ceftriaxone market share in the near future.
The burden of various major chronic diseases across the globe is expected to rise significantly in the next few years. Increase in incidence of urinary tract infections, acute bacterial otitis media, intra-abdominal infections, and other diseases is a key factor driving the demand for ceftriaxone injections during the forecast period. Often, bacteria (germs) that enter the bladder cause urinary tract infections (UTIs). UTIs are also referred to as bladder infections. UTIs are frequent, particularly in women. At some point in their lives, more than half of women are likely to experience at least one UTI. These are painful and dangerous conditions. Increase in usage of ceftriaxone in the treatment of urinary tract infection is anticipated to augment ceftriaxone market expansion.
According to the National Center for Biotechnology Information, approximately 80% of all children are expected to experience a case of otitis media during their lifetime, and between 80% and 90% of all children would have otitis media with an effusion before school age. Furthermore, increase in geriatric population, especially in developed countries, is likely to fuel the demand for ceftriaxone injections. Bacterial infections are more common in people over the age of 65.
In terms of indication, the urinary tract infections segment accounted for significant market share in 2021. Urinary tract infections are more common in the adult population. According to Aging Health, the incidence rate of UTIs among women over 65 is over 10%. The incidence rate increases to 30% among women over 85. Furthermore, growth in preference for ceftriaxone in developing countries for the treatment of urinary tract infections is likely to drive the segment.
Based on distribution channel, the hospital pharmacies segment is likely to account for significant share of the global ceftriaxone market during the forecast period. Hospitals are increasingly preferred for the treatment of bacterial infections due to the availability of favorable reimbursement policies. Therefore, the segment is anticipated to grow at a rapid pace during the forecast period. Ceftriaxone is used in injection form, which requires a physician’s prescription. It is most commonly used in hospitals.
North America accounted for the largest share of around 44.0% in 2021. The region is likely to be a highly lucrative market during the forecast period. North America's global dominance can be ascribed to the increase in incidence rate of bacterial infections. Additionally, high adoption of new technologically advanced products, significant health care expenditure, early availability of advanced technologies, and favorable funding by governments and charitable trusts for healthcare research are projected to boost the ceftriaxone market size in the next few years. The U.S. dominated the market in North America owing to the presence of key players.
Asia Pacific is anticipated to record the fastest market development during the forecast period. The industry in the region is anticipated to expand at a high CAGR from 2022 to 2031 due to the large patient base in countries such as India and China.
The global business is fragmented, with the presence of a large number of players. Most of the ceftriaxone market companies are investing significantly in research & development activities, primarily to introduce generic types of ceftriaxone. Expansion of the product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the industry.
Hikma Pharmaceuticals plc, Qilu Pharmaceutical Co. Ltd., Novartis AG, Baxter International, Inc., Aurobindo Pharma, ACS DOBFAR S.P.A., Orchid Pharma, Nectar Lifesciences Ltd., and Lupin Pharmaceuticals, Inc. are the prominent players operating in the global ceftriaxone market.
Each of the ceftriaxone manufacturers has been profiled in the market report based on parameters such as company overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2021 |
US$ 1.7 Bn |
|
Forecast (Value) in 2031 |
More than US$ 2.2 Bn |
|
Growth Rate (CAGR) |
2.9% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The industry was valued at US$ 1.7 Bn in 2021
It is projected to reach more than US$ 2.2 Bn by 2031
The CAGR is expected to be 2.9% from 2022 to 2031
Increase in incidence of urinary tract infection and rise in awareness about bacterial infection
North America is likely to account for a major share from 2022 to 2031
Hikma Pharmaceuticals plc, Qilu Pharmaceutical Co. Ltd., Novartis AG, Baxter International, Inc., Aurobindo Pharma, ACS DOBFAR S.P.A., Orchid Pharma, Nectar Lifesciences Ltd., and Lupin Pharmaceuticals, Inc.
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Market Overview
3.2. Introduction
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Ceftriaxone Market Forecast
4.5. Global Ceftriaxone Market Outlook
5. Market Outlook
5.1. Key Market Trends
5.2. Regulatory Scenario, by Region
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ceftriaxone Market Analysis and Forecast, by Indication
6.1. Introduction
6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
6.3. Global Ceftriaxone Market Forecast, by Indication
6.3.1. Urinary Tract Infections
6.3.2. Intra-abdominal Infections
6.3.3. Endocarditis
6.3.4. Acute Bacterial Otitis Media
6.3.5. Meningitis
6.3.6. Pneumonia
6.3.7. Others
7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel
7.1. Introduction
7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Ceftriaxone Market Analysis, by Distribution Channel
8. Global Ceftriaxone Market Analysis, by Region
8.1. Global Ceftriaxone Market Analysis, by Region
8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
8.3. Global Ceftriaxone Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America Ceftriaxone Market Analysis
9.1. North America Ceftriaxone Market Overview
9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
9.3. North America Ceftriaxone Market Forecast, by Country
9.3.1. U.S.
9.3.2. Canada
9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
9.5. North America Ceftriaxone Market Forecast, by Indication
9.5.1. Urinary Tract Infections
9.5.2. Intra-abdominal Infections
9.5.3. Endocarditis
9.5.4. Acute Bacterial Otitis Media
9.5.5. Meningitis
9.5.6. Pneumonia
9.5.7. Others
9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
10. Europe Ceftriaxone Market Analysis
10.1. Europe Ceftriaxone Market Overview
10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
10.5. Europe Ceftriaxone Market Forecast, by Indication
10.5.1. Urinary Tract Infections
10.5.2. Intra-abdominal Infections
10.5.3. Endocarditis
10.5.4. Acute Bacterial Otitis Media
10.5.5. Meningitis
10.5.6. Pneumonia
10.5.7. Others
10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
11. Asia Pacific Ceftriaxone Market Analysis
11.1. Asia Pacific Ceftriaxone Market Overview
11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia & New Zealand
11.3.5. Rest of Asia Pacific
11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
11.5.1. Urinary Tract Infections
11.5.2. Intra-abdominal Infections
11.5.3. Endocarditis
11.5.4. Acute Bacterial Otitis Media
11.5.5. Meningitis
11.5.6. Pneumonia
11.5.7. Others
11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
12. Latin America Ceftriaxone Market Analysis
12.1. Latin America Ceftriaxone Market Overview
12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
12.5. Latin America Ceftriaxone Market Forecast, by Indication
12.5.1. Urinary Tract Infections
12.5.2. Intra-abdominal Infections
12.5.3. Endocarditis
12.5.4. Acute Bacterial Otitis Media
12.5.5. Meningitis
12.5.6. Pneumonia
12.5.7. Others
12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
13. Middle East & Africa Ceftriaxone Market Analysis
13.1. Middle East & Africa Ceftriaxone Market Overview
13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of Middle East & Africa
13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
13.5.1. Urinary Tract Infections
13.5.2. Intra-abdominal Infections
13.5.3. Endocarditis
13.5.4. Acute Bacterial Otitis Media
13.5.5. Meningitis
13.5.6. Pneumonia
13.5.7. Others
13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
14. Competitive Analysis
14.1. Competition Matrix
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profile
14.3.1. Hikma Pharmaceuticals plc
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Qilu Pharmaceutical Co. Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. Baxter International, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Aurobindo Pharma
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Strategic Overview
14.3.5.4. SWOT Analysis
14.3.6. ACS DOBFAR S.P.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Strategic Overview
14.3.6.4. SWOT Analysis
14.3.7. Orchid Pharma
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Strategic Overview
14.3.7.4. SWOT Analysis
14.3.8. Nectar Lifesciences Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Lupin Pharmaceuticals, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis
List of Tables
Table 01: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 02: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 03: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 06: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 09: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 10: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 12: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 13: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 18: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Ceftriaxone Market Value Share, by Indication (2021)
Figure 03: Global Ceftriaxone Market Value Share, by Distribution Channel (2021)
Figure 04: Global Ceftriaxone Market Value Share, by Region (2021)
Figure 05: Global Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
Figure 06: Global Ceftriaxone Market Attractiveness Analysis, by Indication, 2022–2031
Figure 07: Global Ceftriaxone Market Revenue (US$ Mn), by Urinary Tract Infections, 2017–2031
Figure 08: Global Ceftriaxone Market Revenue (US$ Mn), by Intra-abdominal Infections, 2017–2031
Figure 09: Global Ceftriaxone Market Revenue (US$ Mn), by Endocarditis, 2017–2031
Figure 10: Global Ceftriaxone Market Revenue (US$ Mn), by Acute Bacterial Otitis Media, 2017–2031
Figure 11: Global Ceftriaxone Market Revenue (US$ Mn), by Meningitis, 2017–2031
Figure 12: Global Ceftriaxone Market Revenue (US$ Mn), by Pneumonia, 2017–2031
Figure 13: Global Ceftriaxone Market Revenue (US$ Mn), by Others, 2017–2031
Figure 14: Global Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 15: Global Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 16: Global Ceftriaxone Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031
Figure 17: Global Ceftriaxone Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031
Figure 18: Global Ceftriaxone Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031
Figure 19: Global Ceftriaxone Market Value Share Analysis, by Region, 2021 and 2031
Figure 20: Global Ceftriaxone Market Attractiveness Analysis, by Region, 2022–2031
Figure 21: North America Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 22: North America Ceftriaxone Market Value Share Analysis, by Country, 2021 and 2031
Figure 23: North America Ceftriaxone Market Attractiveness Analysis, by Country, 2022–2031
Figure 24: North America Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
Figure 25: North America Ceftriaxone Market Attractiveness Analysis, by Indication, 2022–2031
Figure 26: North America Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 27: North America Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 28: Europe Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 29: Europe Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 30: Europe Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 31: Europe Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
Figure 32: Europe Ceftriaxone Market Attractiveness Analysis, by Indication, 2022–2031
Figure 33: Europe Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 34: Europe Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 35: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 36: Asia Pacific Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 37: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 38: Asia Pacific Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
Figure 39: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Indication, 2022–2031
Figure 40: Asia Pacific Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 41: Asia Pacific Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 42: Latin America Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 43: Latin America Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 44: Latin America Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 45: Latin America Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
Figure 46: Latin America Ceftriaxone Market Attractiveness Analysis, by Indication, 2022–2031
Figure 47: Latin America Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 48: Latin America Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 49: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 50: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 51: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 52: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Indication, 2021 and 2031
Figure 53: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Indication, 2022–2031
Figure 54: Middle East & Africa Ceftriaxone Market Value Share Analysis, by Distribution Channel, 2021 and 2031
Figure 55: Middle East & Africa Ceftriaxone Market Attractiveness Analysis, by Distribution Channel, 2022–2031
Figure 56: Global Ceftriaxone Market Share, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Ceftriaxone Market
